KLOW is a four-peptide research blend co-lyophilized for in vitro investigation of converging tissue-repair, inflammation, and extracellular-matrix pathways. Composition: KPV + BPC-157 + GHK-Cu + TB-500 - allowing study of NF-kappaB, VEGF, copper-ECM, and actin-thymosin pathways in a single experimental matrix.
Every batch of KLOW Blend is sent to an accredited independent laboratory before it ships. Each of the four constituent peptides - KPV, BPC-157, GHK-Cu, and TB-500 - is verified for identity, purity, and net content prior to co-lyophilization. Here is exactly what we screen for, and the certificate that proves it.
Four mechanistically distinct peptides studied for converging effects on inflammation, angiogenesis, extracellular matrix, and cytoskeletal dynamics
KPV (Lys-Pro-Val), the C-terminal tripeptide of alpha-MSH, has been reported in vitro to block the importin-alpha/p65 NF-kappaB nuclear translocation pathway, suppressing pro-inflammatory cytokine transcription independently of melanocortin receptors.
BPC-157, a 15-amino-acid fragment derived from gastric Body Protection Compound, is reported in preclinical models to upregulate VEGFR2, modulate the nitric oxide system, and influence angiogenic and gut-barrier signaling.
GHK-Cu (Gly-His-Lys-Cu2+) is a copper-binding tripeptide reported to modulate gene expression related to collagen synthesis, decorin, antioxidant defense, and extracellular matrix remodeling in dermal fibroblast cultures.
Selected preclinical findings across the four constituent peptides
Primary domains of KLOW-component investigation
KPV and BPC-157 are both studied in intestinal-epithelial models for effects on tight-junction integrity, mucosal inflammation, and DSS-colitis paradigms - making KLOW a candidate matrix for studying combinatorial gut-barrier modulation in vitro.
Dalmasso et al. 2008 ↗BPC-157 and KPV literature describes effects on zonulin, occludin, and claudin expression in intestinal and epithelial barrier models, used to probe permeability changes under inflammatory challenge.
Sikiric et al. 2018 ↗All four KLOW components have been studied for effects on NF-kappaB, cytokine release, and oxidative-stress markers, supporting investigation of multi-target inflammation pharmacology in cell and tissue models.
Pickart & Margolina 2017 ↗KLOW serves as a research scaffold for studying additive or synergistic effects between distinct peptide pharmacologies (NF-kappaB, VEGF, copper-ECM, actin-thymosin) without requiring four separate reconstitutions.
Goldstein et al. 2005 ↗Per-component sequence, mass, and analytical profile
Common questions about the KLOW Blend research matrix
Peer-reviewed publications and clinical studies database